“Global Vaccine Contract Manufacturing market set to grow to $2.9bn by 2023” says new Visiongain report

02 April 2019
Pharma

Visiongain has launched a new pharma report Global Vaccine Contract Manufacturing Market Report 2019-2029: Paediatric Vaccines, Adult Vaccines, Influenza Vaccines, Therapeutic Vaccines, Downstream Processing, Fill & Finish Operations, Analytical & QC Studies, Packaging, Upstream Processing, Mammalian Expression Systems, Bacterial Expression Systems, Yeast Expression Systems, Baculovirus/Insect Expression Systems, Other Upstream Processing.

The vaccine manufacturing sector has traditionally been conservative in its approach, relying on traditional methods for vaccine production. The vaccine shortages of recent years that were caused by national pandemics (such as avian flu) highlighted the shortcomings of some of these production methods. The increasing demand for vaccines will make it vital for the vaccine manufacturing industry to develop more-efficient methods for producing vaccines.

The lead analyst of the report commented "Major fluctuations in demand are seen in the case of influenza, as was seen during pandemics over the last decade. The shortage of the number of doses was attributed to the slow and low-yielding traditional egg-based manufacturing technology that has been used for several decades by vaccine manufacturers. This egg-based manufacturing method has been meeting the demand for seasonal influenza vaccines but has been inefficient for meeting the rise in the global demand during pandemics.

Several small and large vaccine manufacturers are now exploring innovative technology platforms for improving the scale of production of the influenza vaccine. Most of the recent developments in manufacturing platforms have been for this vaccine type. Thus, the vaccine manufacturing techniques are evolving, and this will stimulate the growth of the vaccine contract manufacturing market during the forecast period."

Leading companies featured in the report include AbbVie, Baxter BioPharma Solutions, Boehringer Ingelheim, Catalent, Charles River Laboratories, Evonik Degusa, IDT Biologika, Lonza, Meridian Life Science, Nipro Corporation and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“The colon targeting drug delivery market will grow with exponential growth of 14% over the forecast period from 2020-2030”, says Visiongain

The colon targeting drug delivery market has been used various polymers including biodegradable polymers, guar gum, pectin, chondroitin sulfate, dextran, chitosan, cyclodextrin, inulin, amylose, locust bean gum, and others

23 September 2019

Read

“Global Diagnostic Imaging market set to grow to $32bn by 2024” says Visiongain report

Diagnostic imaging technology such as MRI and CT scans has become more precise and accessible, due to which radiology has increasingly become a key foundation of modern medicine.

20 September 2019

Read

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
Do NOT follow this link or you will be banned from the site!